WallStSmart

Aclarion Inc (ACON)vsR1 RCM Inc (RCM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

R1 RCM Inc generates 3163357% more annual revenue ($2.46B vs $77,880). ACON leads profitability with a 0.0% profit margin vs -2.5%. RCM earns a higher WallStSmart Score of 39/100 (F).

ACON

Avoid

29

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 6.8
Piotroski: 3/9Altman Z: 2.53

RCM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 5.7Quality: 6.0
Piotroski: 6/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ACON.

RCMUndervalued (+27.7%)

Margin of Safety

+27.7%

Fair Value

$19.79

Current Price

$14.31

$5.48 discount

UndervaluedFair: $19.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACON1 strengths · Avg: 10.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

RCM1 strengths · Avg: 8.0/10
Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Areas to Watch

ACON4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$8.27M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

RCM4 concerns · Avg: 2.8/10
PEG RatioValuation
2.064/10

Expensive relative to growth rate

Operating MarginProfitability
3.8%3/10

Operating margin of 3.8%

Return on EquityProfitability
-2.2%2/10

ROE of -2.2% — below average capital efficiency

EPS GrowthGrowth
-99.3%2/10

Earnings declined 99.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : ACON

The strongest argument for ACON centers on Price/Book. Revenue growth of 11.3% demonstrates continued momentum.

Bull Case : RCM

The strongest argument for RCM centers on Price/Book. Revenue growth of 14.7% demonstrates continued momentum.

Bear Case : ACON

The primary concerns for ACON are EPS Growth, Market Cap, Profit Margin.

Bear Case : RCM

The primary concerns for RCM are PEG Ratio, Operating Margin, Return on Equity.

Key Dynamics to Monitor

ACON profiles as a value stock while RCM is a turnaround play — different risk/reward profiles.

ACON carries more volatility with a beta of 1.19 — expect wider price swings.

RCM is growing revenue faster at 14.7% — sustainability is the question.

RCM generates stronger free cash flow (60M), providing more financial flexibility.

Bottom Line

RCM scores higher overall (39/100 vs 29/100) and 14.7% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aclarion Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Aclarion Inc (ACON) is a pioneering healthcare technology company that specializes in non-invasive diagnostics, focusing on musculoskeletal conditions through innovative imaging and advanced data analytics. By harnessing machine learning, Aclarion provides healthcare professionals with actionable insights that enhance clinical outcomes while optimizing costs within treatment pathways. Positioned at the vanguard of the digital health transformation, Aclarion is poised to meet the increasing demand for effective diagnostic solutions, significantly enhancing the standard of patient care in an evolving healthcare landscape. Its commitment to improving patient management establishes Aclarion as a key player in the future of healthcare delivery.

Visit Website →

R1 RCM Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

R1 RCM Inc (RCM) is a leading provider of technology-driven revenue cycle management solutions that significantly enhance the financial performance of healthcare organizations across the United States. By leveraging advanced analytics and deep industry expertise, R1 RCM offers comprehensive services that optimize billing processes and improve operational efficiency for hospitals and outpatient facilities alike. The company’s innovative approach not only enhances revenue capture but also elevates patient experiences, establishing R1 RCM as a critical player in the evolving healthcare sector. With a strong emphasis on expanding its service offerings and increasing market share, R1 RCM is strategically positioned to capitalize on the growing demand for sophisticated revenue cycle management services.

Want to dig deeper into these stocks?